PL379561A1 - Niesedatywny agonista Ó-2, 1-(2, 3-dimetylo-fenylo)-etylo-1, 3-dihydro-imidazolo-2-tion - Google Patents

Niesedatywny agonista Ó-2, 1-(2, 3-dimetylo-fenylo)-etylo-1, 3-dihydro-imidazolo-2-tion

Info

Publication number
PL379561A1
PL379561A1 PL379561A PL37956104A PL379561A1 PL 379561 A1 PL379561 A1 PL 379561A1 PL 379561 A PL379561 A PL 379561A PL 37956104 A PL37956104 A PL 37956104A PL 379561 A1 PL379561 A1 PL 379561A1
Authority
PL
Poland
Prior art keywords
agonist
imizadole
nonsedating
thione
dihydro
Prior art date
Application number
PL379561A
Other languages
English (en)
Inventor
Ken Chow
Todd M. Heidelbaugh
John E. Donello
Daniel W. Gil
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL379561A1 publication Critical patent/PL379561A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL379561A 2003-09-12 2004-08-20 Niesedatywny agonista Ó-2, 1-(2, 3-dimetylo-fenylo)-etylo-1, 3-dihydro-imidazolo-2-tion PL379561A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50256203P 2003-09-12 2003-09-12
US10/891,953 US7141597B2 (en) 2003-09-12 2004-07-15 Nonsedating α-2 agonists

Publications (1)

Publication Number Publication Date
PL379561A1 true PL379561A1 (pl) 2006-10-16

Family

ID=34278841

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04781753T PL1663206T3 (pl) 2003-09-12 2004-08-20 1-(2,3-dimetylo-fenylo)-etylo-1,3-dihydro-imidazolo-2-tion jako alfa 2A agonista bez działania uspokajającego
PL379561A PL379561A1 (pl) 2003-09-12 2004-08-20 Niesedatywny agonista Ó-2, 1-(2, 3-dimetylo-fenylo)-etylo-1, 3-dihydro-imidazolo-2-tion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL04781753T PL1663206T3 (pl) 2003-09-12 2004-08-20 1-(2,3-dimetylo-fenylo)-etylo-1,3-dihydro-imidazolo-2-tion jako alfa 2A agonista bez działania uspokajającego

Country Status (25)

Country Link
US (4) US7141597B2 (pl)
EP (2) EP1800679B1 (pl)
JP (1) JP4698591B2 (pl)
KR (1) KR101145046B1 (pl)
CN (1) CN100417379C (pl)
AT (2) ATE358479T1 (pl)
AU (1) AU2004279332B2 (pl)
BR (1) BRPI0413719A (pl)
CA (1) CA2537832C (pl)
CO (1) CO5680444A2 (pl)
CY (1) CY1107608T1 (pl)
DE (2) DE602004030051D1 (pl)
DK (2) DK1800679T3 (pl)
ES (1) ES2285522T3 (pl)
IL (1) IL173530A (pl)
MX (1) MXPA06002668A (pl)
NO (1) NO20060667L (pl)
NZ (1) NZ545181A (pl)
PL (2) PL1663206T3 (pl)
PT (1) PT1663206E (pl)
RU (1) RU2345987C2 (pl)
SI (1) SI1663206T1 (pl)
TW (1) TWI337999B (pl)
WO (1) WO2005034946A1 (pl)
ZA (1) ZA200601002B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) * 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20060293359A1 (en) * 2003-06-25 2006-12-28 Allergan, Inc. Methods and compositions for the treatment of diabetes
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006036480A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
WO2006036497A2 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
US20090182026A1 (en) * 2005-06-29 2009-07-16 Allergan, Inc. Alpha 2 adrenergic agonists
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
BRPI0710674A2 (pt) * 2006-04-07 2011-08-23 Allergan Inc composições incluindo fármacos relativamente insolúveis em água/não umectáveis e métodos para usar as mesmas
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
DK2160386T3 (da) 2007-05-23 2012-08-27 Allergan Inc Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
US20110028559A1 (en) * 2007-07-06 2011-02-03 Fang Wenkui K Substituted fluoroethyl ureas as alpha 2 adrenergic agents
KR20100071990A (ko) * 2007-08-15 2010-06-29 알러간, 인코포레이티드 녹내장 및 통증과 같은 질환의 처치에 유용한 헤테로사이클 치환된 융합 카르보사이클
KR101642520B1 (ko) * 2007-08-15 2016-07-25 알러간, 인코포레이티드 아드레날린성 화합물
JP2010536780A (ja) * 2007-08-15 2010-12-02 アラーガン インコーポレイテッド 治療化合物
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20110269805A1 (en) * 2007-10-18 2011-11-03 Gil Daniel W Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009089448A1 (en) * 2008-01-11 2009-07-16 Allergan, Inc. Therapeutic disulfide compounds for treating pain and diabetes
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
WO2010093910A1 (en) 2009-02-13 2010-08-19 Allergan, Inc. 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
WO2020222188A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
US20230404979A1 (en) * 2020-10-26 2023-12-21 Rush University Medical Center Alpha-2 adrenergic receptor agonists to reduce mortality and improve outcomes in viral respiratory syndromes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150266A (ja) * 1986-12-12 1988-06-22 Mitsui Petrochem Ind Ltd ベンジルイミダゾ−ル誘導体
ZA881807B (en) 1987-03-20 1988-09-05 Merrell Dow Pharmaceuticals Inc. Method for reducing reperfusion injury with imidazol-2-thiones
US4868197A (en) * 1987-03-20 1989-09-19 Merrell Dow Pharmaceuticals Inc. Reducing reperfusion injury with 1,3-dihydro-4-methyl-5-(4-methylthio)benzoyl)-2H-imidazol-2-thione
US4798843A (en) 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
AU2313995A (en) 1994-05-02 1995-11-29 Zeneca Limited Herbicidal hydroxybenzyl-substituted heteroaryl compounds and derivatives thereof
BR9813381A (pt) * 1997-12-04 2000-10-03 Allergan Sales Inc "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c"
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists

Also Published As

Publication number Publication date
US20080176918A1 (en) 2008-07-24
US8022226B2 (en) 2011-09-20
ATE487477T1 (de) 2010-11-15
PT1663206E (pt) 2007-06-22
US7141597B2 (en) 2006-11-28
ES2285522T3 (es) 2007-11-16
AU2004279332A1 (en) 2005-04-21
ZA200601002B (en) 2007-04-25
BRPI0413719A (pt) 2006-10-17
KR20060119970A (ko) 2006-11-24
EP1663206B1 (en) 2007-04-04
MXPA06002668A (es) 2006-06-06
CA2537832C (en) 2012-01-24
CA2537832A1 (en) 2005-04-21
EP1663206A1 (en) 2006-06-07
ATE358479T1 (de) 2007-04-15
AU2004279332B2 (en) 2010-10-07
DE602004005720T2 (de) 2007-12-27
US20050059721A1 (en) 2005-03-17
DE602004030051D1 (de) 2010-12-23
CY1107608T1 (el) 2013-03-13
IL173530A (en) 2010-05-31
SI1663206T1 (sl) 2007-06-30
KR101145046B1 (ko) 2012-05-21
RU2345987C2 (ru) 2009-02-10
RU2006113600A (ru) 2007-11-10
NZ545181A (en) 2009-07-31
HK1092704A1 (en) 2007-02-16
JP4698591B2 (ja) 2011-06-08
CN100417379C (zh) 2008-09-10
US20110034525A1 (en) 2011-02-10
DK1800679T3 (da) 2011-02-07
IL173530A0 (en) 2006-07-05
EP1800679A3 (en) 2009-01-21
NO20060667L (no) 2006-04-06
EP1800679A2 (en) 2007-06-27
US7312238B2 (en) 2007-12-25
TWI337999B (en) 2011-03-01
DK1663206T3 (da) 2007-07-30
HK1104979A1 (en) 2008-02-01
CO5680444A2 (es) 2006-09-29
US20070004790A1 (en) 2007-01-04
EP1800679B1 (en) 2010-11-10
DE602004005720D1 (de) 2007-05-16
WO2005034946A1 (en) 2005-04-21
PL1663206T3 (pl) 2007-08-31
TW200526591A (en) 2005-08-16
CN1849118A (zh) 2006-10-18
JP2007505111A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
IL173530A0 (en) Nonsedating a-2 agonisti-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadole-2-thione
MXPA05009367A (es) Antagonistas del receptor opioide.
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
IL163911A0 (en) Naltrexone hydrochloride compositions
MXPA06000675A (es) Derivado de quinolona o sal del mismo.
EP2289894A3 (en) Pyrrolo-triazine compounds useful as kinase inhibitors
AU2003263599A1 (en) Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
HUP0302226A3 (en) Substituted pyrrolopyridinone dervatives useful as phosphodiesterse inhibitors, their intermediates and pharmaceutical compositions containing the compounds
AU2003239389A1 (en) Opioid receptor antagonists
SE0200919D0 (sv) Chemical compounds
EP2394992A3 (en) Substituted piperidine compounds and methods of their use
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GEP20074127B (en) Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
WO2005065047A3 (en) Stable oral composition containing desloratadine
IL166730A0 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-Ä1,3,4-oxadiazol-2-ylÜphenyl)pyridine-3-sulphonamide as an anticancer agent
PL1636217T3 (pl) 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors
NO994135L (no) Kinoksalindioner
DE60137451D1 (de) N-substituierte Amide als NK1 Rezeptor Antagonisten
AU2003211397A1 (en) Cyclic amine compound and ccr3 inhibitory drug containing the same as active ingredient
TW200505468A (en) Agent for improving hepato-bililary dysfunction
AU2003284772A1 (en) PHARMACEUTICAL COMPOSITION FOR CONTROLING THE STABILITY OF HIF-1Alpha
MX9702532A (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
WO2004037163A3 (en) STERICALLY-AWKWARD β-LACTAMASE INHIBITORS

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)